UCB (OTCMKTS:UCBJF) Shares Gap Down – Here’s What Happened

UCB SA (OTCMKTS:UCBJF) shares gapped down before the market opened on Monday . The stock had previously closed at $269.84, but opened at $255.52. UCB shares last traded at $255.52, with a volume of 525 shares changing hands.

Analyst Ratings Changes

A number of research firms have recently weighed in on UCBJF. Piper Sandler restated a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Jefferies Financial Group upgraded UCB to a “hold” rating in a research report on Monday, August 3rd. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

UCB Stock Down 0.6%

The business has a fifty day moving average of $289.41 and a 200 day moving average of $297.98. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.